SCHEMBL7915410

SCHEMBL7915410

Fc1ccc(-c2cncs2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 3/20 0.49
DYRK1A Q13627 2/20 0.44
HDAC4 P56524 1/20 0.42
SLC6A3 Q01959 4/20 0.41
SLC6A2 P23975 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DYRK2 Q92630 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
ALOX5 P09917 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPK14 Q16539 1/20 0.39
AR P10275 1/20 0.39
MAPT P10636 1/20 0.38
CYP19A1 P11511 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32671911 0.82 CD38 (0.53) CD38DYRK1AHDAC4CYP11B1CYP11B2
SCHEMBL17643727 0.82 CD38 (0.53) CD38DYRK1AHDAC4CYP11B1CYP11B2
SCHEMBL48894 0.79 DYRK1A (0.55) CD38DYRK1AHDAC4SMN1; SMN2DYRK2
SCHEMBL1872880 0.79 DYRK1A (0.55) CD38DYRK1AHDAC4CYP11B1CYP11B2
SCHEMBL4541085 0.77 CD38 (0.49) CD38DYRK1ASLC6A3SLC6A2SMN1; SMN2
SCHEMBL8309617 0.77 CD38 (0.49) CD38DYRK1ASLC6A3SLC6A2SMN1; SMN2
SCHEMBL19219067 0.77 DYRK1A (0.53) CD38DYRK1ACYP11B1CYP11B2SMN1; SMN2
SCHEMBL5179594 0.77 ESR1 (0.50) DYRK1AHDAC4POLBSMN1; SMN2DYRK2
SCHEMBL999315 0.77 HDAC8 (0.46) CD38DYRK1AHDAC4SLC6A3SLC6A2
Ammonia Solution, Strong SCHEMBL28177501 0.77 DYRK1A (0.53) CD38DYRK1AHDAC4SMN1; SMN2DYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270202-A1 SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-08-28 US disclosed
EP-4545524-A1 SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2025-04-30 EP disclosed
EP-3315502-B1 C,O-SPIRO ARYL GLYCOSIDE COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2024-07-31 EP disclosed
WO-2023246944-A1 SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 中国科学院上海药物研究所 2023-12-28 WO disclosed
CN-117285524-A Substituted 4-amino isoindoline compounds, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-12-26 CN disclosed
WO-2023183444-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC (US) 2023-09-28 WO disclosed
EP-4195928-A1 USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII BASF SE (DE) 2023-06-21 EP disclosed
WO-2022033906-A1 USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII BASF SE (DE) 2022-02-17 WO disclosed
US-10550143-B2 C,O-spiro aryl glycoside compounds, preparation therefor and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-02-04 US disclosed
CN-107709332-B C, O-spiro aryl glycoside compound and preparation and application thereof 中国科学院上海药物研究所 2019-12-20 CN disclosed
CN-1558898-A Antiviral agent ��Ұ����ҩ��ʽ���� 2004-12-29 CN disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 US disclosed
US-6096144-A TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-08-01 US disclosed
US-5858571-A TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-12 US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550143-B2 C,O-spiro aryl glycoside compounds, preparation therefor and use thereof SLC5A2, SLC5A1, GLP1R CD38 1431/4885DYRK1A 4094/4885HDAC4 775/4885
US-20250270202-A1 SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF CUL4B, CUL3, CUL4A CD38 4082/4885DYRK1A 3244/4885HDAC4 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.